In the cited clinical trials, IL-13Rα2-directed CART was infused into the surgical cavity after resection of recurrent GBM, whereas EGFRvIII- and HER2-directed CART were administered intravenously. The gene discussed is IL13RA2; the disease is glioblastoma.